Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker
nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC)
patients with favorable response to induction chemotheray(IC), determining whether
radiotherapy combined with nimotuzumab was non-inferior to CCRT and may provide new evidence
for individualized comprehensive treatment of locoregionally advanced NPC.